UVA Health Studied Histotripsy Outcomes
Researchers analyzed 30-day mortality rates for patients who underwent noninvasive liver tumor treatment.
Updated on Oct. 4, 2026 in Cancer
UVA Health researchers reported an 11% 30-day mortality rate among 972 patients who underwent histotripsy for liver tumors between 2023 and 2026. The findings were published in JAMA Network Open on August 5, 2026.
Why it matters
Understanding mortality outcomes following noninvasive procedures helps clinicians refine patient selection criteria for those with advanced disease. Researchers noted that the high proportion of metastatic cases suggests underlying disease burden may influence survival rates.
A study of 972 patients found that 11% died within 30 days of undergoing histotripsy. Nearly 70% of these patients had metastatic cancer that had spread to the liver from other parts of the body.
The players
UVA Health
This academic health system in Charlottesville conducted the research on histotripsy outcomes.
JAMA Network Open
This peer-reviewed medical journal published the findings of the UVA Health study.
The details
Histotripsy destroys cancer cells by directing focused sound waves into tissue to create destructive bubbles. The procedure, which is performed on an outpatient basis, showed low rates of laboratory toxicity and complications throughout the study.
Timeline
The FDA cleared histotripsy for clinical use in 2023.
Patients underwent the procedure between 2023 and 2026.
Study results were published on August 5, 2026.
The Big Picture
This research follows the 2023 FDA clearance of histotripsy, marking an early phase of assessing how this noninvasive sound-wave technology performs in real-world clinical settings. The data helps establish benchmarks for future studies as the medical community evaluates its role in cancer care.
Patients and their families may need to discuss the risks and expected outcomes of noninvasive procedures with their oncologists to ensure the treatment fits their overall health status. The research highlights the importance of patient selection for those with metastatic disease.
The takeaway
Clinical studies emphasize that advanced metastatic cancer, rather than the procedure itself, remains a primary factor in mortality for liver tumor patients. Consult with medical specialists to understand how new outpatient technologies align with specific cancer treatment plans.
Further reading
For additional context on local oncology advancements, visit Cancer.
Source note: This article includes information reported by SciTechDaily.
